CD19 across 7 cancers
CD19 is on the target list of 7 of the briefings. A drug aimed at it carries an FDA label naming the disease in 5, and is approved for some indication in 7. In the reference cohorts of the 5 with a mutation landscape it is altered in at least 5% of patients in 0 and in under 2% in 5 (Diffuse large B-cell lymphoma, Acute lymphoblastic leukemia, Follicular lymphoma, Mantle cell lymphoma, Chronic lymphocytic leukemia) — a target there by expression, dependency or drug label, not by mutation.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials | Altered in the reference cohort |
|---|---|---|---|---|---|
| Diffuse large B-cell lymphoma | approved here Lisocabtagene Maraleucel, Loncastuximab Tesirine, Tafasitamab, Tisagenlecleucel | approved | 14 | 50 via CD19 | 0.0% mut n=1001 |
| Acute lymphoblastic leukemia | approved here Brexucabtagene Autoleucel, Obecabtagene Autoleucel, Tisagenlecleucel | approved | 14 | 97 via CD19 | 0.0% mut · 0.15% amp · 0.15% del n=137 |
| Follicular lymphoma | approved here Lisocabtagene Maraleucel, Tafasitamab, Tisagenlecleucel | approved | 14 | 27 via CD19 | n=193 |
| Mantle cell lymphoma | approved here Brexucabtagene Autoleucel, Lisocabtagene Maraleucel | approved | 14 | 25 via CD19 | 0.0% mut n=29 |
| Chronic lymphocytic leukemia | approved here Lisocabtagene Maraleucel | approved | 14 | 50 via CD19 | 0.19% mut n=1074 |
| Burkitt lymphoma | approved elsewhere | approved | 14 | 5 via CD19 | no landscape |
| Waldenström macroglobulinaemia | approved elsewhere | approved | 14 | 2 via CD19 | no landscape |
"Approved here" means a drug Open Targets records as aimed at CD19 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov. The last column is the disease's mutation landscape: non-silent mutation, high-level amplification and deep deletion as percentages of the reference cohort's patients, each over its own denominator; "not on panel" means the reference cohort could not have called the gene.